MDM2, MDMX and p53 in oncogenesis and cancer therapy
- M. Wade, Yao-Cheng Li, G. Wahl
- BiologyNature Reviews. Cancer
- 1 February 2013
This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.
Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis
- I. Legnini, G. Di Timoteo, I. Bozzoni
- BiologyMolecules and Cells
- 6 April 2017
The p53 orchestra: Mdm2 and Mdmx set the tone.
- M. Wade, Yunyuan V. Wang, G. Wahl
- BiologyTrends in Cell Biology
- 1 May 2010
Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells*
- M. Wade, E. Wong, Mengjia Tang, J. Stommel, G. Wahl
- BiologyJournal of Biological Chemistry
- 3 November 2006
Tumors that express wild-type P53 provide a target for therapies designed to reactivate P53 function, and the role of Hdmx expression in sensitivity to Nutlin is evaluated, implying that HDMx is an important determinant of the outcome of P53 activation.
Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration.
- H. Wu, M. Wade, L. Krall, J. Grisham, Y. Xiong, T. van Dyke
- Biology, MedicineGenes & Development
- 1 February 1996
These results provide the first in vivo evidence that appropriate p21 levels are critical in normal development and further implicate p21 in the control of multiple cell-cycle phases.
A stapled p53 helix overcomes HDMX-mediated suppression of p53.
- F. Bernal, M. Wade, L. Walensky
- BiologyCancer Cell
- 16 November 2010
Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?
This review discusses current models of p53 regulation by Mdm2 and Mdmx and presents the rationale for design of future MDMx-specific therapeutics based on knowledge of its structure and biological functions.
Quantitative analyses reveal the importance of regulated Hdmx degradation for P53 activation
- Yunyuan V. Wang, M. Wade, E. Wong, Yao-Cheng Li, L. Rodewald, G. Wahl
- BiologyProceedings of the National Academy of Sciences
- 24 July 2007
The data indicate that the damage-activated switch in Hdm2 ubiquitin ligase preference from P53 to itself and Hdmx is central to P53 activation, which greatly limits P53 activity in cells growing in culture.
Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA
- A. Subramanian, A. Andronache, Yao-Cheng Li, M. Wade
- BiologyOncoTarget
- 21 February 2016
The data uncover a novel level at which the BCL2 family is regulated and suggest targeting MARCH5-dependent signaling will be an effective strategy for treatment of BH3 mimetic-resistant tumors, even in the presence of high MCL1.
...
...